



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

June 30, 2020

**To,
Listing Department,
BSE Limited**

Sub: Outcome of Board Meeting held on June 30, 2020

We wish to inform you that the Board of Directors of the Company, at their just concluded meeting have inter, alia transacted the following businesses:

1. Approved the audited standalone financials for the half year and year ended March 31, 2020 and took note of the Auditors Report thereon
2. Approved the audited consolidated financials for the half year and year ended March 31, 2020 and took note of the Auditors Report thereon

Please find enclosed the standalone and consolidated financial results for the half year and year ended March 31, 2020 along with the Audit Reports issued by the statutory auditors of the Company.

The meeting commenced at 3:00 P.M and concluded at 9:45 P.M.

This is for your information and dissemination to the public.

FOR VANTA BIOSCIENCE LIMITED


**DOPESH RAJA MULAKALA
MANAGING DIRECTOR
DIN: 01176660**



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED 31st MARCH 2020

Sr.No	Particulars	STANDALONE				
		6 MONTH ENDED			YEAR ENDED	
		31.03.2020 (Audited)	30.09.2019 (Un Audited)	31.03.2019 (Audited)	31.03.2020 (Audited)	31.03.2019 (Audited)
1	Income					
	Revenue from Operation	681.24	730.07	640.26	1411.31	1242.48
	Other Income	10.88	0.00	15.32	10.88	22.88
	Total Revenue	692.12	730.07	655.58	1422.19	1265.36
2	Expenses					
	a) Cost of material Consumed	36.46	81.46	63.91	117.92	139.80
	b) Employee Benfit Expenses	256.79	237.2	234.01	493.99	415.39
	c) Financial Cost	97.55	97.28	89.53	194.83	168.85
	d) Depreciation and amortization Exp	78.14	40.75	34.80	118.89	71.09
	e) other expenses	173.13	194.63	169.40	367.76	360.47
	Total Expenses	642.07	651.32	591.65	1293.39	1155.60
3	Profit/(Loss) from ordinary activities before Exceptional Items (1-2)	50.06	78.75	63.93	128.80	109.76
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) from ordinary activities before tax (3+4)	50.06	78.75	63.93	128.80	109.76
6	Tax Expenses					
	a) Current Tax	(6.47)	(15.17)	(14.07)	(21.64)	(22.89)
	b) MAT Credit Availed	9.45	0.00	0.00	9.45	0.00
	c) Deferred Tax	(12.72)	(6.09)	(9.78)	(18.81)	(17.49)
7	Net Profit/(Loss) from ordinary activities after tax (5-6)	40.32	57.49	40.08	97.80	69.38
8	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00	0.00
9	Total Comprehensive Income/(Loss) Net of Tax (7+8)	40.32	57.49	40.08	97.80	69.38
10	Paid up Equity share capital (face value of Rs.10/-)	631.20	631.20	631.20	631.20	631.20
11	Reserve excluding Revaluation reserve					
	Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised)					
	a) Basic (Rs.)	0.64	0.91	0.77	1.55	1.17
	b) Diluted (Rs.)	0.64	0.91	0.77	1.55	1.17
	Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised)					
	a) Basic (Rs.)	0.64	0.91	0.77	1.55	1.17
	b) Diluted (Rs.)	0.64	0.91	0.77	1.55	1.17

Place : Hyderabad
Date : 30.06.2020

For and on behalf of Board of Directors

Dopesh Raja Mulakala
Dopesh Raja Mulakala
Managing Director





Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.

Tel : +91 40 6657 5454, 2790 3226

Fax : +91 40 2790 8708

Website : www.vantabio.com

Email : info@vantabio.com

CIN No. : U74999TG2016PLC109280

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED 31st MARCH 2020						
(Rupees. In Lacs)						
Sr.No	Particulars	CONSOLIDATED				
		6 MONTH ENDED			YEAR ENDED	
		31.03.2020 (Audited)	30.09.2019 (Un Audited)	31.03.2019 (Audited)	31.03.2020 (Audited)	31.03.2019 (Audited)
1	Income					
	Revenue from Operation	681.24	733.07	646.06	1414.31	1248.28
	Other Income	10.99	0.00	15.40	10.99	22.96
	Total Revenue	692.23	733.07	661.46	1425.30	1271.24
2	Expenses					
	a) Cost of material Consumed	36.46	81.46	63.91	117.92	139.80
	b) Employee Benefit Expenses	254.84	252.54	234.01	507.38	415.39
	c) Financial Cost	97.54	97.28	89.57	194.82	168.89
	d) Depreciation and amortization Exp	78.14	40.75	34.80	118.89	71.09
	e) other expenses	170.69	181.41	174.87	352.10	365.94
	Total Expenses	637.67	653.44	597.16	1291.11	1161.11
3	Profit/(Loss) from ordinary activities before Exceptional Items (1-2)	54.56	79.63	64.30	134.19	110.13
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) from ordinary activities before tax (3+4)	54.56	79.63	64.30	134.19	110.13
6	Tax Expenses					
	a) Current Tax	(5.24)	(19.14)	(14.16)	(24.38)	(22.98)
	b) MAT Credit Availed	9.45	0.00	0.00	9.45	0.00
	c) Deferred Tax	(12.72)	(6.09)	(9.78)	(18.81)	(17.49)
7	Net Profit/(Loss) from ordinary activities after tax (5-6)	46.05	54.40	40.36	100.45	69.65
8	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00	0.00
9	Total Comprehensive Income/(Loss) Net of Tax (7+8)	46.05	54.40	40.36	100.45	69.65
10	Paid up Equity share capital (face value of Rs.10/-)	631.20	631.20	631.20	631.20	631.20
11	Reserve excluding Revaluation reserve					
	Earning per share of (before extra ordinary items)					
	Rs.10 Each (Not Anualised)					
12	a) Basic (Rs.)	0.73	0.86	0.78	1.59	1.19
	b) Diluted (Rs.)	0.73	0.86	0.78	1.59	1.19
	Earning per share of after extra ordinary items)					
	Rs.10 Each (Not Anualised)					
	a) Basic (Rs.)	0.73	0.86	0.78	1.59	1.19
	b) Diluted (Rs.)	0.73	0.86	0.78	1.59	1.19

For and on behalf of Board of Directors

M. D. Raju
Dopesh Raja Mufakala
Managing Director



Place : Hyderabad

Date : 30.06.2020



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

STATEMENT OF ASSETS & LIABILITIES AS ON 31st MARCH 2020					
Sr.No.	Particulars	STANDALONE		CONSOLIDATED	
		31.03.2020	31.03.2019	31.03.2020	31.03.2019
		Audited	Audited	Audited	Audited
A	Equity and Liabilities				
1	EQUITY				
	a) Equity share capital	631.20	631.20	631.20	631.20
	b) Reserve & Surplus	1712.80	1593.30	1715.73	1593.57
	c) Non Controlling/Minority Interest	0.00	0.00	98.97	98.14
	Sub total Equity	2344.00	2224.50	2445.90	2322.91
2	LIABILITIES				
	Non Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	1042.72	1216.63	1365.14	1216.63
	b) Provisions	0.00	0.00	0.00	0.00
	c) Deferred tax Liabilities	59.07	40.26	59.07	40.26
	d) Other Non Current Liabilities	0.00	0.00	0.00	0.00
	Sub Total -Non Current Liabilities	1101.79	1256.89	1424.21	1256.89
3	Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	188.40	0.00	188.40	0.00
	ii) Trade Payables	49.08	45.73	49.08	45.73
	b) Other Current Liabilities	469.13	260.99	741.75	262.20
	c) Provisions	6.18	12.17	8.12	12.32
	d) Current tax Liabilities(net)	0.00	0.00	0.00	0.00
	Sub Total -Non Current Liabilities	712.79	318.89	987.35	320.25
	Total Equity and Liabilities	4158.58	3800.28	4857.46	3900.05
B	ASSETS				
1	Non Current Assets				
	a) Property, Plant and Equipment	1589.39	1303.75	1589.39	1673.59
	b) Capital Work in Progress	0.00	369.84	700.47	0.00
	c) Other Intangible assets	486.23	486.23	486.23	486.23
	d) Other Intangible assets under development	0.00	0.00	0.00	0.00
	e) Investment in associates and joint ventures	0.00	0.00	0.00	0.00
	f) Financial Assets	0.00	0.00	0.00	0.00
	i) Investments in Subsidiary	300.00	199.99	0.00	0.00
	ii) Loans	0.00	0.00	0.00	0.00
	iii) Other Financial Assets	0.00	0.00	0.00	0.00
	g) Deferred tax assets (net)	0.00	0.00	0.00	0.00
	h) Other non current assets	35.04	35.04	96.76	35.04
	Sub Total Non-Current Assets	2410.66	2394.85	2872.85	2194.86
2	Current Assets				
	a) Inventories	1400.73	924.42	1400.73	924.42
	b) Financial Assets				
	i) Investments	0.00	195.00	0.00	195.00
	ii) Trade Receivable	135.59	156.40	139.15	156.40
	iii) Bank, Cash and Cash equivalents	8.67	28.43	19.51	326.63
	iv) Loans & Advances	170.45	89.62	392.42	91.18
	iv) Othe Financial Assets	0.00	0.00	0.00	0.00
	c) Current Tax Assets (net)	0.00	0.00	0.00	0.00
	d) Other Current Assets	32.48	11.56	32.80	11.56
	Sub Total Current Assets	1747.92	1405.43	1984.61	1705.19
	Total Assets	4158.58	3800.28	4857.46	3900.05

For and on behalf of Board of Directors

(Signature)

Dopesh Raja Mulakala

Managing Director

Research Center
PIN: 01176660

K2-B, 1st Cross Street, SIPCOT Industrial Complex,
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
Tel : 044 6790 1600

Place : Hyderabad
Date : 30.06.2020



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.

Tel : +91 40 6657 5454, 2790 3226

Fax : +91 40 2790 8708

Website : www.vantabio.com

Email : info@vantabio.com

CIN No. : U74999TG2016PLC109280


Cash Flow statement for the period ended 31st March,2020		(Rupees in Lacs)			
Particulars	STANDALONE		CONSOLIDATED		
	For the Year ended 31.03.2020	For the Year ended 31.03.2019	For the Year ended 31.03.2020	For the Year ended 31.03.2019	
A. Cash Flow from Operating Activities					
Profit before exceptional , Extraordinary items and Tax	128.80	109.76	134.19	110.31	
Adjustment for:					
Depreciation	118.89	71.10	118.89	71.10	
Finance Charges	194.83	168.85	194.82	168.85	
Gain/Loss on foreign Exchange fluctuation	=	=	=	=	
Sub total	313.72	239.95	313.71	239.95	
Operating profit Before Working Capital Changes	442.52	349.71	447.90	350.26	
Adjustment for:					
(Increase) /Decrease in Inventories	(476.31)	(621.98)	(476.31)	(621.97)	
(Increase) /Decrease in Trade receivables	20.80	(123.38)	17.25	(130.48)	
Increase /(Decrease) in trade payable	205.49	132.15	403.31	139.92	
(Increase) /Decrease Loans & Advances	(70.60)	2.35	(353.05)	(96.53)	
(Increase) /Decrease in Current Investment	195.00	255.00	195.00	255.00	
Sub total	(125.62)	(355.86)	(213.80)	(454.06)	
Cash Generated from operations	316.90	(6.15)	234.10	(103.80)	
Net Cash Flow from Operating Activities	316.90	(6.15)	234.10	(103.80)	
B: Cash Flow from Investing Activities					
Purchase of Fixed Assets	(34.69)	(247.58)	(34.69)	(247.58)	
Capital Work In progress	=	=	(700.47)	=	
Capital Work In progress-R&D	=	=	=	=	
proceeds from sale of Fixed Assets	=	=	=	=	
Investment in Subsidiaries	(100.00)	(200.00)	=	(302.00)	
Purchase of other Non current Investments	=	=	=	=	
Net Cash Flow from Investing Activities	(134.69)	(447.58)	(735.16)	(549.58)	
C: Cash Flow from Financing Activities					
Increase /(Decrease) in Unsecured Loan	=	=	110.00	98.00	
Increase /(Decrease) in Working capital	188.40	(49.85)	128.39	(49.85)	
Increase /(Decrease) in Term Loan	(173.90)	218.62	173.91	218.62	
Increase /(Decrease) in share capital	=	58.40	=	458.40	
Increase /(Decrease) in share Premium	=	438.00	=	438.00	
Finance Charges	(194.83)	(168.85)	(194.82)	(168.85)	
Net Cash Flow from Financing Activities	(180.33)	496.32	217.48	994.32	
Actual Payment of Income Tax	(21.64)	(22.89)	(23.54)	(23.04)	
D: Net Increase/Decrease in Cash and cash Equivalents	(19.76)	19.70	(307.12)	317.90	
Opening of Cash & Cash Equivalents	28.43	8.73	326.63	8.73	
Closing Balance of Cash & Cash Equivalents	8.67	28.43	19.51	326.63	

See accompanying notes to the financial statements
As per our report of even date annexed.

Place : Hyderabad
Date : 30.06.2020

For and on behalf of Board of Directors

Dopesh Raja Mulakala
Dopesh Raja Mulakala
Managing Director
DIN:01176660



Research Center :

K2-B, 11th Cross Street, SIPCOT Industrial Complex,
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
Tel : 044 6790 1600



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

Notes to Standalone and consolidated financial statements:

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30th June, 2020.
2. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
3. Statement of Assets and Liabilities as on 31st March 2020 is enclosed herewith.
4. Statement of Cash flow for period ended 31st March 2020 is enclosed herewith.
5. There were no investor complaints received/pending as at 31st March, 2020.
6. The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.

The Company during the previous year issued 5,84,000 equity shares of Rs. 10/- each at a premium of Rs. 75/— on preferential basis and their utilization is as follows:

(Amount In Rs Lakhs)

Proceeds from Preferential Allotment	496.40
Utilization	
Investment/ Loans in Subsidiary	343.00
General Corporate and Working Capital	123.40
Issue Expense	25.00
Balance- Investment in Liquid funds	5.00
Total	496.40

There are no unutilized /outstanding amount now

8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
9. The figures of the half year are the balancing figures between audited figures in respect of full financial year and the published six months figures for 30th September, 2019.





Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280


10. Impact of Covid-19 on Business of the company

It is envisaged that impact of the COVID-19 pandemic, including that on financial condition and results of operations, future operations, capital and financial resources, liquidity, assets, internal financial control over financial reporting and disclosure controls and procedures, demand for products/services etc. would not be too significant in case of our company..

Though, there has been a lag in receivables from clients and also in availability of raw material for conducting some specific studies due to restriction placed on movement and transportation. However, there is no long term major impact as such on the overall set up and functioning of the Company as on date.

Further, it is anticipated that with work and transportation related relaxations being notified for various parts of the country and gradual start of economic activities would eventually result in cash flows and availability of raw materials as and when required for continuation of our studies.

11.The said results are uploaded on the website of the Company www.vantabio.com and on BSE ltd.





INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF VANTA BIOSCIENCE LIMITED

Report on the audit of the Consolidated Financial Results

Opinion:

We have audited the accompanying Statement of Consolidated Financial Results of **VANTA BIOSCIENCE LIMITED** ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), for the half year ended 31.03.2020 and for the period from 01.04.2019 to 31.03.2020 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, associates and jointly controlled entities, the Statement:

- i. includes the financial results of the following entities:
 - Vanta Clinical Research Limited (Subsidiary)
 - Vayam Research Solutions Limited (Step Subsidiary)
- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- iii. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the half year ended 31.03.2020 and for the period from 01.04.2019 to 31.03.2020.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.



E-mail : matheshca@yahoo.co.in



Management's Responsibilities for the Consolidated Financial Results:

These half yearly financial results as well as the year to date consolidated financial results have been prepared on the basis of the consolidated financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results:

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.



E-mail : mateshea@yahoo.co.in



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



E-mail : mateshca@yahoo.co.in



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters:

The consolidated Financial Results include the audited Financial Results of **2 (Two)** subsidiaries, whose Financial Results/ financial information reflects total assets of Rs. 1,109.17 Lacs as at 31st March 2020, total revenue of Rs. 18.60 Lacs and Rs. 49.11 Lacs and net profit after tax of Rs. 6.56 Lacs and Rs. 3.48 Lacs for the half year ended 31st March 2020 and for the period from 01.04.2019 to 31.03.2020 respectively, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on Financial statements/Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS



B V RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad
Date: 30.06.2020
UDIN: 20026967AAAADP6039



INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF VANTA BIOSCIENCE LIMITED

Report on the audit of the Standalone Financial Results

Opinion:

We have audited the accompanying standalone half yearly financial results of **Vanta Bioscience Limited** (the company) for the half year ended 31.03.2020 and the year to date results for the period from 01.04.2019 to 31.03.2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the half year ended 31.03.2020 as well as the year to date results for the period from 01.04.2019 to 31.03.2020.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results:

These half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the standalone financial statements.

The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down





in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results:

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.







- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS




B V RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad
Date: 30.06.2020
UDIN: 20026967AAAADO5413



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

June 30, 2020

To,
Listing Department,
BSE Limited

Sub: Declaration regarding audit report with unmodified opinion

In compliance with Regulation 33 of the Listing Regulations, the Board hereby declares/certifies that the statutory auditors of the Company have submitted their Audit Report on the standalone and consolidated financial results of the Company for FY 2019-20 with an unmodified and unqualified opinion.

This is for your information and dissemination to the public.

FOR VANTA BIOSCIENCE LIMITED

A handwritten signature in black ink, appearing to read 'Dopesha Raja', is written over the printed name.

**DOPESH RAJA MULAKALA
MANAGING DIRECTOR
DIN: 01176660**



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

June 30, 2020

**To,
Listing Department,
BSE Limited**

Sub: Submission regarding no deviation or variation in the use of proceeds of Preferential Issue

We hereby submit that there is no deviation or variation in the use of proceeds of preferential issue from the objects as stated in the explanatory statement of Notice of EGM held on September 29, 2018.

Kindly refer notes to accounts of standalone and consolidated financial statements for category wise details of the projected utilization and actual utilization of proceeds from preferential allotment.

We further submit that the entire funds raised from the Preferential Issue has been completely utilized for the purposes it was raised and that there are no funds unutilized/outstanding now.

The above was also taken note by the Audit Committee and the Board of the Company in their meeting held on June 30, 2020.

This is for your information and dissemination to the public.

FOR VANTA BIOSCIENCE LIMITED

A handwritten signature in black ink, appearing to read 'Dopesha Raja', is written over a light blue horizontal line.

**DOPESH RAJA MULAKALA
MANAGING DIRECTOR
DIN: 01176660**